The Journal of Allergy and Clinical Immunology
Volume 115, Issue 5 , Pages 1089-1090 , May 2005

COX-2–selective inhibitor valdecoxib induces severe allergic skin reactions

References 

  1. Dieppe PA, Ebrahim S, Martin RM, Juni P. Lessons from the withdrawal of rofecoxib. BMJ. 2004;329:867–868
  2. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol. 2003;111:913–921
  3. Kruse R, Ruzicka T, Grewe M. Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib: results of oral provocation tests in patients with NSAID hypersensitivity. Acta Derm Venereol. 2003;83:183–185
  4. Sanchez Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol. 2001;87:201–204
  5. Grob M, Sheidegger P, Wuthrich B. Allergic skin reaction to celecoxib. Dermatology. 2000;201:383
  6. Munoz-Bellido FJ, Terron M, Leon A. Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance. Allergy. 2003;58:1072–1075
  7. Chavez ML, DeKorte CJ. Valdecoxib: a review. Clin Ther. 2003;25:817–851
  8. Alonso JC, Ortega JD, Gonzalo MJ. Cutaneous reaction to oral celecoxib with positive patch test. Contact Dermatitis. 2004;50:48–49
  9. Goeschke B, Braathen LR. Acute generalized exanthematic pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far. Dermatology. 2004;209:53–56
  10. Wilkinson DS, Fregert S, Magnusson H, Bandmann HJ, Calnan CD, Cronin E, et al. Terminology of contact dermatitis. Acta Derm Venereol. 1970;50:287–292

PII: S0091-6749(05)00116-8

doi: 10.1016/j.jaci.2004.12.1135

The Journal of Allergy and Clinical Immunology
Volume 115, Issue 5 , Pages 1089-1090 , May 2005

Article Tools

* Image Usage & Resolution